Finance

Lists
002294:SHE
Shenzhen Salubris Pharmaceuticals Co Ltd
30,84 CNY
+0,85%
(+0,26) 1D
16 ოქტ, 15:04:54 GMT+8  ·   CNY
All symbols
SymbolPriceChange% Change
Generating top insights for 002294...
Open
30,83 CNY
High
31,80 CNY
Low
30,82 CNY
Mkt. cap
33,85 მლრდ.
Avg. vol.
9,55 მლნ.
Volume
27,91 მლნ.
Dividend
1,78%
Quarterly dividend
0,14 CNY
Ex-dividend date
26 მაი. 2026
P/E ratio
51,05
52-wk high
70,99 CNY
52-wk low
29,25 CNY
EPS
0,60 CNY
Shares outstanding
1,11 მლრდ.
No. of employees
4 ათ.
Open
30,83 CNY
High
31,80 CNY
Low
30,82 CNY
Mkt. cap
33,85 მლრდ.
Avg. vol.
9,55 მლნ.
Volume
27,91 მლნ.
Dividend
1,78%
Quarterly dividend
0,14 CNY
Ex-dividend date
26 მაი. 2026
P/E ratio
51,05
52-wk high
70,99 CNY
52-wk low
29,25 CNY
EPS
0,60 CNY
Shares outstanding
1,11 მლრდ.
No. of employees
4 ათ.
News stories
From web sources and news partners
Profile
Shenzhen Salubris Pharmaceuticals is a Chinese pharmaceutical company. Founded in November 1998 and based in Shenzhen, it has a market cap of US$4.4 billion, 3,121 employees and annual sales of $553 million as of 2019. Shenzhen Salubris is headed by the billionaire Ye Chenghai. Wikipedia
About Shenzhen Salubris Pharmaceuticals Co Ltd
CEO-
Employees4,09 ათ.
Founded3 ნოე. 1998
Headquarters-
SectorPharmaceutical industry
Previous reportsAll values in CNY
Loading Previous Earnings...
Revenue
Net income
All values in CNY
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
1,11 მლრდ.
1,11 მლრდ.
1,23 მლრდ.
1,25 მლრდ.
Cost of goods sold
279,29 მლნ.
302,88 მლნ.
287,67 მლნ.
343,20 მლნ.
Cost of revenue
279,29 მლნ.
302,88 მლნ.
287,67 მლნ.
343,20 მლნ.
Research and development expenses
127,63 მლნ.
176,44 მლნ.
131,32 მლნ.
139,63 მლნ.
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
486,77 მლნ.
568,30 მლნ.
551,61 მლნ.
596,71 მლნ.
Operating expense
595,66 მლნ.
770,11 მლნ.
694,36 მლნ.
749,18 მლნ.
Total operating expenses
874,96 მლნ.
1,07 მლრდ.
982,03 მლნ.
1,09 მლრდ.
Operating income
235,37 მლნ.
38,38 მლნ.
246,41 მლნ.
158,32 მლნ.
Other non operating income
-14,62 მლნ.
13,83 მლნ.
-5,27 მლნ.
5,40 მლნ.
EBT including unusual items
234,09 მლნ.
5,21 მლნ.
255,47 მლნ.
142,37 მლნ.
EBT excluding unusual items
246,15 მლნ.
72,00 მლნ.
252,02 მლნ.
160,96 მლნ.
Income tax expense
18,06 მლნ.
-56,18 მლნ.
29,65 მლნ.
-22,28 მლნ.
Effective tax rate
7,72%
-1 078,48%
11,60%
-15,65%
Other operating expenses
-17,83 მლნ.
34,11 მლნ.
9,61 მლნ.
16,33 მლნ.
Net income
215,63 მლნ.
70,80 მლნ.
225,27 მლნ.
161,82 მლნ.
Net profit margin
19,42%
6,37%
18,34%
12,94%
Earnings per share
-
-
-
-
Interest and investment income
26,87 მლნ.
37,76 მლნ.
15,05 მლნ.
12,29 მლნ.
Interest expense
-4,88 მლნ.
-7,50 მლნ.
-4,17 მლნ.
-4,97 მლნ.
Net interest expenses
22,00 მლნ.
30,27 მლნ.
10,88 მლნ.
7,32 მლნ.
Depreciation and amortization charges
-
-
-
-
EBITDA
325,52 მლნ.
135,48 მლნ.
343,52 მლნ.
257,90 მლნ.
Gain or loss from assets sale
-983,77 ათ.
3,03 მლნ.
-
166,24 ათ.
AI content may include mistakes. Learn more
Google აპები